Thermo Fisher Scientific and Quintiles Create Joint Venture to Provide Integrated Response Technology Services


WALTHAM, Mass., May 21 /-- Thermo Fisher Scientific Inc. (NYSE:TMO) and Quintiles Transnational Corp. today announced the creation of a joint venture, called Cenduit, that provides seamless, integrated Interactive Response Technology (IRT) services during the clinical trial phase of drug development. IRT is a technology platform that integrates patient interaction systems through a combination of telephone response, Web interface and handheld electronic patient diaries. The use of IRT is expected to grow as pharmaceutical companies look to streamline and better control increasingly complex drug development processes.

"Our companies have been looking for an opportunity to leverage the particular service strengths we bring to the drug development process," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "With Cenduit, we have combined two leaders -- the clinical supply chain expertise of our Fisher Clinical Services business with the clinical development expertise of Quintiles -- to offer a scalable, seamless technology platform." The name "Cenduit" signifies the channel through which information can move directly and freely.

Thermo Fisher contributes to the joint venture its Fisher Clinical Services IRT operations in three locations -- Horsham, U.K.; Allentown, Penn., USA; and Basel, Switzerland. Quintiles brings its IRT operations in Bangalore, India, and Research Triangle Park, N.C., USA, which will also serve as Cenduit's headquarters.

Jogin Desai, chief executive officer of Cenduit, said, "This joint venture brings together best-in-class technology, exceptional customer service and global clinical trial expertise to give biotechnology and pharmaceutical companies a seamless, integrated 'one-stop' service for support of their clinical development programs. Our efficiency and experience in IRT services and clinical project management offers the drug development industry a conduit to the broadest, most accurate, real-time view of every detail in the process - and a very competitive solution." Desai previously served as executive director of Quintiles Cardiac Safety Services.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With 17,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.quintiles.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE:TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

FCMN Contact: investorrelations@thermo.com

Source: Thermo Fisher Scientific Inc.

CONTACT: Media, Lori Gorski, +1-781-622-1242, lori.gorski@thermofisher.com, or Investors, Ken Apicerno, +1-781-622-1111, ken.apicerno@thermofisher.com, both of Thermo Fisher Scientific Inc.

Web site: www.thermofisher.com/
http://www.quintiles.com/

All Topics